BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

We are excited by the acceptance of our first filing for tislelizumab in liver cancer, commented Xiaobin Wu, Ph.D., General Manager of China and President of BeiGene.